3 Penny Stocks to Watch Today, September 8
TipRanks (Tue, 8-Sep 10:49 AM ET)
Immuron to launch PROIBS in the United States
Globe Newswire (Fri, 4-Sep 6:00 AM ET)
Immuron Reports FY26 Preliminary Results
Globe Newswire (Fri, 28-Aug 6:00 AM ET)
Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream
Globe Newswire (Wed, 19-Aug 7:00 AM ET)
Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream
Globe Newswire (Tue, 18-Aug 7:00 AM ET)
Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar
Globe Newswire (Mon, 20-Jul 6:00 AM ET)
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
Globe Newswire (Thu, 16-Jul 6:00 AM ET)
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
Globe Newswire (Mon, 6-Jul 6:00 AM ET)
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Immuron Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol IMRN.
As of September 9, 2026, IMRN stock price declined to $1.76 with 691,755 million shares trading.
IMRN has a beta of 1.38, meaning it tends to be more sensitive to market movements. IMRN has a correlation of 0.03 to the broad based SPY ETF.
IMRN has a market cap of $14.21 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, IMRN traded as high as $5.96 and as low as $.68.
IMRN has underperformed the market in the last year with a return of -6.4%, while SPY returned +18.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in IMRN shares. However, IMRN has outperformed the market in the last 3 month and 2 week periods, returning +46.7% and +54.4%, while SPY returned +3.4% and -0.5%, respectively. This indicates IMRN has been having a stronger performance recently.
IMRN support price is $1.73 and resistance is $1.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMRN shares will trade within this expected range on the day.
